Celcuity Inc. announced that Eric Lindquist joined the company as its Chief Business Officer. Prior to joining Celcuity, Mr. Lindquist was the Global Vice President of Oncology and Rare Disease for Natera Inc. He was responsible for launching their oncology diagnostic product, Signatera, to the pharmaceutical industry and executed more than 30 Signatera related agreements within the first year of its launch. Eric previously served as the Global Vice President of Customer and Companion Diagnostics at Asuragen, a molecular testing company, and as Director, Business Development and Alliances for Companion Diagnostics, at Roche Diagnostics.